CD19/CD38 Bispecific Antibodies for Selective B-Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody therapeutics face limitations in clinical efficacy for complex diseases like cancer, particularly due to the multifactorial nature of these diseases, and current treatments targeting immunosuppressive B cells can cause severe side effects such as anemia and lymphopenia.
Innovation Solution
Development of bispecific antibodies that selectively bind to both CD19 and CD38, targeting immunosuppressive B cells to modulate the anti-tumor immune response, thereby reducing immunosuppression and enhancing treatment efficacy while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monospecific antibodies targeting B-cell markers (e.g., CD19 or CD38) are used, then B-cell depletion is achieved, but severe side effects such as anemia and lymphopenia occur
Solution Approach 1:
The patent applies multi-functionality by designing bispecific antibodies that simultaneously target two different B-cell markers (CD19 and CD38). This allows a single antibody molecule to perform multiple functions: selectively depleting immunosuppressive B-cells while maintaining or enhancing anti-tumor immune responses, thereby achieving therapeutic efficacy while reducing off-target side effects associated with monospecific antibodies
2Reliability
If conventional antibody therapeutics are used for complex diseases like cancer, then treatment is administered, but clinical efficacy is limited due to the multifactorial nature of these diseases
Solution Approach 1:
The bispecific antibodies provide multi-functionality by simultaneously engaging two different B-cell targets, enabling the therapy to address multiple aspects of B-cell mediated immunosuppression in cancer. This enhanced versatility allows the treatment to be more effective against the multifactorial nature of complex diseases compared to conventional monospecific antibodies
Solution Approach 2:
The patent employs parameter changes by modifying the antibody structure to possess dual specificity for CD19 and CD38 markers. This structural parameter change enables the antibody to bind two different antigens simultaneously, fundamentally altering its functional parameters to achieve superior clinical efficacy in treating complex cancers
Data Source
AI summary
Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.